nach oben

Erschienen in:

01.09.2014 | Original Paper

Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population

verfasst von: Nataliya Babyshkina, Elena Malinovskaya, Stanislav Patalyak, Olga Bragina, Natalia Tarabanovskaya, Artem Doroshenko, Elena Slonimskaya, Vladimir Perelmuter, Nadejda Cherdyntseva

Erschienen in: Medical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this retrospective study was to evaluate the objective clinical response (cOR), pathological complete response (pCR), and progression-free survival (PFS) in 231 Russian patients with four subtypes of breast cancer treated with neoadjuvant chemotherapy. About 130 (56.3 %) patients received anthracycline-based, 56 (24.2 %) capecitabine-containing (CAX), 28 (12.1 %) taxotere and 17 (7.4 %) non-anthracycline-containing chemotherapy regimens at the Tomsk Cancer Research Institute between 2000 and 2010. Tumors were subtyped according to the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) immunohistochemical data. The majority of tumors (48.9 %) were ER+/PR+ and HER2-negative (HR+/HER2−), 10.4 % were ER+ PR+ and HER2-positive (HR+/HER2+), 9.1 % were ER−/PR− and HER2-overexpressed (HER2-enriched) and 31.6 % were ER-/PR- and HER2-negative (triple negative). Both cOR and pCR were significantly higher in the triple-negative tumors compared to the other subtypes (P = 0.021 and P = 0.033, respectively). Among the four chemotherapy regimens, only CAX regimen had a predictive value for cOR (HR 2.30, 95 % CI 1.16–4.58, P = 0.009). Multivariate regression analysis showed that the triple-negative subtype (HR 2.54, 95 % CI 1.06–1.42, P = 0.011) and CAX regimen (HR 3.01, 95 % CI 1.01–1.46, P = 0.002) were significantly associated with cOR. No association between patient’s PFS and a tumor subtype was observed. However, there was a trend for a prolonged PFS among patients with cOR (P = 0.056). Our data indicate a potentially better prognosis for triple-negative breast cancer patients if treated with the CAX neoadjuvant regimen.

Pisareva LF, Odyntsova IN, Kuderek BK. Epidemiological features of breast cancer in Western Siberian and Far East region. Tomsk: Tomsk University Co; 2006.

Davydov MI, Aksel EM. Cancer statistics in Russia and CIS in 2009. JNN Blokhin Russian Cancer Research Center RAMS. 2011;22:9–123.

Semiglazov VF. New approaches to the treatment of breast cancer. Vopr Onkol. 2013;59(3):288–91.PubMed

Untch M, von Minckwitz G. Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological. J Natl Cancer Inst Monogr. 2011;43:138–41. doi:10.1093/jncimonographs/lgr028.CrossRef

Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(15):1747–9. doi:10.1200/JCO.2011.41.3161.PubMedCrossRef

Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci. 2013;33(2):262–5. doi:10.1007/s11596-013-1108-9.PubMedCrossRef

Hayashi Y, Takei H, Nozu S, Tochigi Y, Ichikawa A, Kobayashi N, Kurosumi M, Inoue K, Yoshida T, Nagai SE, Oba H, Tabei T, Horiguchi J, Takeyoshi I. Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett. 2013;5(1):83–9.PubMedPubMedCentral

Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J, Weigel RJ. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg. 2013;206(1):2–7. doi:10.1016/j.amjsurg.2012.10.025.PubMedCrossRefPubMedCentral

Rea D, Tomlins A, Francis A. Time to stop operating on breast cancer patients with pathological complete response? Eur J Surg Oncol. 2013;39(9):924–30. doi:10.1016/j.ejso.2013.06.005.PubMedCrossRef

10.

Lv M, Li B, Li Y, Mao X, Yao F, Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev. 2011;12(9):2411–7.PubMed

11.

Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010;79(5–6):324–30. doi:10.1159/000322192.PubMedCrossRef

12.

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–40. doi:10.1158/1078-0432.CCR-13-0799.PubMedCrossRef

13.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA. Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(1):32–40. doi:10.1007/s00259-013-2515-7.PubMedCrossRef

14.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRef

15.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351–7. doi:10.1200/JCO.2010.31.4930.PubMedCrossRef

16.

Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342–54. doi:10.1016/j.ejca.2012.05.023.PubMedCrossRef

17.

von Minckwitz G. Neoadjuvant chemotherapy in breast cancer-insights from the German experience. Breast Cancer. 2012;19(4):282–8. doi:10.1007/s12282-012-0393-7.CrossRef

18.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140(1):63–71. doi:10.1007/s10549-013-2620-0.PubMedCrossRefPubMedCentral

19.

Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol. 2005;16(2):267–72.PubMedCrossRef

20.

Zhou B, Yang DQ, Xie F. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J (Engl). 2008;121(5):387–91.

21.

Yu Y, Xiang H, He XM, Yang HJ, Zong XY. Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer: a single center experience. Asian Pac J Cancer Prev. 2013;14(4):2401–6.PubMedCrossRef

22.

Moon HG, Im SA, Han W, Oh DY, Han SW, Keam B, Park IA, Chang JM, Moon WK, Cho N, Noh DY. Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression. Breast Cancer Res Treat. 2012;134(3):1133–40. doi:10.1007/s10549-012-2145-y.PubMedCrossRef

23.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27(8):1168–76. doi:10.1200/JCO.2008.18.1024.PubMedCrossRefPubMedCentral

24.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 2010;23(5):1213–20.PubMed

25.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804. doi:10.1200/JCO.2011.38.8595.CrossRef

26.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;. doi:10.1016/S0140-6736(13)62422-8.PubMed

27.

Kucher AN, Ivanova OF, Puzyrev VP, Tsimbalyuk IV, Trotsenko BA. Genetic-demographic characteristics of a contemporary Siberian city Tomsk. Genetika. 1994;30(2):276–81.PubMed

28.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48.PubMed

29.

Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012;14(3):R83.PubMedCrossRefPubMedCentral

30.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.PubMedCrossRef

31.

Redondo CM, Gago-Domínguez M, Ponte SM, Castelo ME, Jiang X, García AA, Fernández MP, Tomé MA, Fraga M, Gude F, Martínez ME, Garzón VM, Carracedo Á, Castelao JE. Breast feeding, parity and breast cancer subtypes in a Spanish cohort. PLoS ONE. 2012;7(7):e40543. doi:10.1371/journal.pone.0040543.PubMedCrossRefPubMedCentral

32.

Tamaki M, Kamio T, Kameoka S, Kojimahara N, Nishikawa T. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. World J Surg Oncol. 2013;11:293. doi:10.1186/1477-7819-11-293.PubMedCrossRefPubMedCentral

33.

Saeed Eyad Fawzi Al, Ghabbban Abdul Rahman Jameel Al, Tunio Mutahir A. The prognostic significance of the luminal A, luminal B, basal and Her 2 Neu subtypes of breast cancer in Saudi women. Open Breast Cancer J. 2013;5:16–22.CrossRef

34.

Timovska YO, Pivnyuk VM, Oliynichenko GP, Anikushko MF, Zachartseva LM, Chekhun VF. Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer. Exp Oncol. 2009;31(4):231–6.PubMed

35.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47. doi:10.1093/annonc/mdr304.PubMedCrossRefPubMedCentral

36.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50–7. doi:10.1016/j.breast.2011.07.008.PubMedCrossRef

37.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef

38.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef

39.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients. Asian Pac J Cancer Prev. 2012;13(8):4119–23.PubMedCrossRef

40.

Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17(9):2411–8. doi:10.1245/s10434-010-1008-1.PubMedCrossRefPubMedCentral

41.

Stickeler E, Pils D, Klar M, Orlowsk-Volk M, Zur Hausen A, Jäger M, Watermann D, Gitsch G, Zeillinger R, Tempfer CB. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. Oncol Rep. 2011;26(4):1037–45. doi:10.3892/or.2011.1392.PubMed

42.

Kang H, Dai Z, Ma X, Bao X, Lin S, Ma H, Liu X, Wang X. Different response to neoadjuvant chemotherapy for different molecular subtypes in patients with locally advanced breast cancer. Chin Ger J Clin Oncol. 2013;12(4):163–6.CrossRef

43.

Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer. 2012;15(2):203–10. doi:10.4048/jbc.2012.15.2.203.PubMedCrossRefPubMedCentral

44.

Kawajiri H, Takashima T, Aomatsu N, Kashiwagi S, Noda S, Onoda N, Ishikawa T, Hirakawa K. Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer. Oncol Lett. 2014;7(3):663–8.PubMedPubMedCentral

45.

Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011;16(12):1675–83. doi:10.1634/theoncologist.2011-0196.PubMedCrossRefPubMedCentral

46.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-Macgregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014;25(2):384–91. doi:10.1093/annonc/mdt525.PubMedCrossRef

47.

Matsubara N, Mukai H, Fujii S, Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat. 2013;137(1):203–12. doi:10.1007/s10549-012-2344-2346.PubMedCrossRef

48.

Zhou YJ, Ying M, He YJ, Liu YQ, Fan ZQ, Fan T, Li JF, Wang TF, Xie YT, Lu AP, Ouyang T. Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients. Zhonghua Yi Xue Za Zhi. 2013;93(22):1711–5.PubMed

49.

Ooe A, Takahara S, Sumiyoshi K, Yamamoto H, Kawai J, Shiba E. Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Breast Dis. 2013;34(1):9–17. doi:10.3233/BD-130345.

50.

Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2013;. doi:10.1007/s12282-013-0474-2.PubMed

51.

Liu WQ, Ye JM, Xu L, Liu Q, Zhao JX, Duan XN, Liu YH. A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer. Zhonghua Wai Ke Za Zhi. 2013;51(8):706–9.PubMed

52.

Zhang GC, Zhang YF, Xu FP, Qian XK, Guo ZB, Ren CY, Yao M. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer. Curr Oncol. 2013;20(3):e180–92. doi:10.3747/co.20.1294.PubMedCrossRefPubMedCentral

53.

Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II–III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs. 2013;22(3):299–307. doi:10.1517/13543784.2013.766715.PubMedCrossRef

54.

Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124(1):133–40. doi:10.1007/s10549-010-1103-9.PubMedCrossRef

55.

Li Q, Jiang Y, Wei W, Yang H, Liu J. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2013;8(1):e53403. doi:10.1371/journal.pone.0053403.PubMedCrossRefPubMedCentral

56.

Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014;. doi:10.1002/cam4.164.PubMedPubMedCentral

57.

Liao Y, Fan Y, Wan Y, Li J, Peng L. Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study. Chemotherapy. 2013;59(3):207–13. doi:10.1159/000356156.PubMedCrossRef

58.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Invest New Drugs. 2012;30(1):408–16. doi:10.1007/s10637-010-9555-7.PubMedCrossRef

59.

Slonimskaya EM, Tarabanovskaya NA, Doroshenko AV, Garbukov EYu, Kokorina YuL. Xeloda in neoadjuvant treatment for operable breast cancer. Siberian J Oncol. 2009;1(31):14–8.

60.

Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer. 2012;. doi:10.1007/s12282-012-0424-4.PubMed

61.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 2011;18(10):2851–7. doi:10.1245/s10434-011-1665-8.PubMedCrossRef

62.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486. doi:10.1186/1471-2407-11-486.PubMedCrossRefPubMedCentral

63.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. Med Oncol. 2009;26(3):372–8. doi:10.1007/s12032-008-9131-6.PubMedCrossRef

64.

Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection. Clin Transl Oncol. 2014;16(4):386–94. doi:10.1007/s12094-013-1088-z.PubMedCrossRef

65.

Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 2013;. doi:10.1007/s12282-013-0482-2.PubMed

66.

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 2013;. doi:10.1007/s12282-013-0511-1.PubMedCentral

67.

Marmé F, Aigner J, Lorenzo Bermejo J, Sinn P, Sohn C, Jäger D, Schneeweiss A. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. Int J Cancer. 2013;133(4):1006–15. doi:10.1002/ijc.28094.PubMedCrossRef

Titel: Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population
verfasst von: Nataliya Babyshkina
Elena Malinovskaya
Stanislav Patalyak
Olga Bragina
Natalia Tarabanovskaya
Artem Doroshenko
Elena Slonimskaya
Vladimir Perelmuter
Nadejda Cherdyntseva
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 9/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0165-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice

Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-γ

High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer

Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population

Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients

A miRNA-binding site single nucleotide polymorphism in the 3′-UTR region of the NOD2 gene is associated with colorectal cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie